Evaluation of the Usefulness of Imaging Methods and 3D Reconstruction in Percutaneous Closure Procedures of PVL.

Balton Sp.zo.o.18 enrolled

Overview

Paravalvular leak (PVL) is a condition that could be treated surgically or by the transcatheter deployment of the occluder devices (plugs). No PVL-specific occluder device is available on the market. VALE consortium plans to design and validate a new PVL dedicated devices (sizing balloon and occluder) in the context of computer 3D modeling, bench testing, preclinical evaluation and clinical research.

Transcatheter closure of PVL has emerged as a new treatment strategy that can be offered to patients with isolated PVL or to those with a very high risk of repeat surgery. The transcatheter approach involves deployment of occlude devices or coils and adopting either a percutaneous or a transapical approach. Limitation of such approach is the fact that no PVL-dedicated device is available on the market, and either vascular-specific plugs or other types of occluders used commonly for closure of ventricular septal defects or patent ductus arteriosus can be used. Several technical issues can make the procedure challenging. The primary problem is the localization and track of the canal which can be very difficult to engage and cross with the guidewire. Also the maneuverability of the guide catheter in often enlarged left atrium and the passage of the occluder device through narrow and serpiginous canal between calcified annulus and sewing ring is challenging. Clearly the limitations of current devices and increasing number of patients with significant PVL warrant the attempts to design and validate new PVL-dedicated devices in the context of computer modeling, bench testing, preclinical evaluation and clinical translation. These devices, as sizing balloon, could significantly simplify and shorten the procedure, decrease the risk of complications and incomplete defect closure as well as optimize cost-effectiveness of the procedure by decreasing number of the occluders.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DEVICE_FEASIBILITY

Masking

NONE

Enrollment

Conditions

PVL - Paravalvular Leak

Interventions

Visualisation and measuring of paravalvular leak.DEVICE

Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The presence of clinically and haemodynamically significant leakage around the surgically implanted cardiac prosthesis in the mitral or aortic position. * Heart surgery (heart team) disability after another cardiac surgery. * Technical feasibility of paravalvular leakage closure according to experienced operator. Exclusion Criteria: * Active endocarditis on artificial valve * Instability of artificial valve * The amount of cavity that prevents effective closure with an occluder * A history of acute coronary syndrome in less than 3 months before enrollment * Confirmed echocardiography of transplatin or transesophageal echocardiography * Hypersensitivity to contrast media * Any condition associated with the expected life expectancy of less than 6 months * Haemorrhagic diathesis * Significant renal impairment (eGFR \<30 mL/min/1.73m2)/chronic kidney disease at \>G3 stage * Pregnancy or lactation * Under 18 years of age * Patient unable or unwilling to give an informed consent to participate in the study

Locations (2)

II Oddział Kliniczny Kardiologii i Interwencji Sercowo-Naczyniowych, Szpital Uniwersytecki w Krakowie

Krakow, Lesser Poland Voivodeship, Poland

III Oddział Kardiologii, Samodzielny Publiczny Szpital Kliniczny nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca

Katowice, Silesian Voivodeship, Poland

Outcomes

Primary Outcomes

Number of subjects with sizing procedure success (efficacy outcome)

Sizing procedure is defined as effective when all following steps: device introduction into the leakage channel, filling in the leakage channel, obtaining a balloon image in the X-ray recording and removal of the balloon without complications are performed.

Time frame: During index procedure

Incidence of a combined investigational device safety endpoint (safety outcome)

Safety of the investigational device defined as the occurrence/frequency of locking, fragmentation of the dimensioning balloon, enlargement of the leakage channel, locking of the mechanical prosthesis disks. Failure to use the investigational device defined as: locking of the dimensional balloon in site, fragmentation of the dimensional balloon, enlargement of the leakage channel dimension directly related to the application of the dimensional balloon, locking of the mechanical prosthesis disks. The failure will be assessed per investigational device and accounted for if at least one of four described events occur. Moreover, the frequency of each event will be additionally assessed and presented in per investigational device analysis.

Time frame: During index procedure

Secondary Outcomes

Frequency of major undesirable cardiovascular events

MACCE defined as: cardiac and non-cardiac death, stroke, TIA, myocardial infarction

Time frame: 30 days observation

Frequency and severity of hemorrhagic complications

The hemorrhagic complications rated using BARC scale during 30 days follow up

Time frame: 30 days observation

Size of paravalvular leakage after procedure

Evaluated in transesophageal echocardiography

Time frame: During index procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.